Lixmabegagene relduparvovec is under clinical development by Lysogene and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Lixmabegagene relduparvovec’s likelihood of approval (LoA) and phase transition for GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) took place on 13 Jul 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Lixmabegagene relduparvovec Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Lixmabegagene relduparvovec overview

Lixmabegagene relduparvovec (LYS-GM101) is under development for the treatment of GM1 gangliosidosis. It is administered intracerebrally. The therapeutic candidate consists of an adeno-associated viral vector serotype rh.10 (AAVrh.10) carrying the human beta-galactosidase gene.

Lysogene overview

Lysogene is a biotechnology company operates clinical research center that offers basic research and clinical development programs. The center offers clinical development of gene therapy for neurodegenerative disorders such as Parkinson and Alzheimer diseases. It also develops models in gene therapy trials for rare pediatric diseases. Lysogene holds expertise in pre-clinical efficacy, gene therapy, toxicology and bio-distribution studies in small and large animal models. The center also develops models and standards to find novel solutions in setting up gene therapy trials for rare pediatric diseases. It has partnership with academic institutions for its research activities. Lysogene is headquartered in Paris, France.

Quick View Lixmabegagene relduparvovec LOA Data

Report Segments
  • Innovator
Drug Name
  • Lixmabegagene relduparvovec
Administration Pathway
  • Intracerebral
Therapeutic Areas
  • Genetic Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.